A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease

Clinica Chimica Acta

Volumn 373, Issue 1-2, 2006, Pages 70-76

  Ndrepepa, Gjin ^a   Kastrati, Adnan ^a   Braun, Siegmund ^a   Koch, Werner ^a   Kölling, Klaus ^a   Mehilli, Julinda ^a   Schömig, Albert ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary artery disease; Diabetes; Homocysteine; Mortality

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; COHORT STUDIES; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 33748198287     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.05.011     Document Type: Article

References (30)

1. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 241 (1979) 2035-2038
2. Tunstall-Pedoe H., Woodward M., Tavendale R., A'Brook R., and McCluskey M.K. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 315 (1997) 722-729 [Erratum in: BMJ 1998316:1881]
3. Stengard J.H., Tuomilehto J., Pekkanen J., Kivinen P., Kaarsalo E., Nissinen A., et al. Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the seven countries study. Diabetologia 35 (1992) 760-765
4. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146 [Erratum in: Circulation 2000;101::1629-1631]
5. Smulders Y.M., Rakic M., Slaats E.H., Treskes M., Sijbrands E.J., Odekerken D.A., et al. Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 22 (1999) 125-132
6. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 18 (1998) 133-138
7. Stehouwer C.D., Gall M.A., Hougaard P., Jakobs C., and Parving H.H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 55 (1999) 308-314
8. Kark J.D., Selhub J., Bostom A., Adler B., and Rosenberg I.H. Plasma homocysteine and all-cause mortality in diabetes. Lancet 353 (1999) 1936-1937
9. Hoogeveen E.K., Kostense P.J., Jakobs C., Dekker J.M., Nijpels G., Heine R.J., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 101 (2000) 1506-1511
10. Soinio M., Marniemi J., Laakso M., Lehto S., and Ronnemaa T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 140 (2004) 94-100
11. Brattstrom L., Wilcken D.E., Ohrvik J., and Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98 (1998) 2520-2526
12. Jacques P.F., Bostom A.G., Wilson P.W., Rich S., Rosenberg I.H., and Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 73 (2001) 613-621
13. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
14. Tan K.C., Chow W.S., Tam S., Bucala R., and Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27 (2004) 223-228
15. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation: Part 1. Diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva
16. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
17. Kolling K., Ndrepepa G., Koch W., Braun S., Mehilli J., Schömig A., et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 93 (2004) 1201-1206
18. Koch W., Ndrepepa G., Mehilli J., Braun S., Burghartz M., Lengnick H., et al. Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. Arterioscler Thromb Vasc Biol 23 (2003) 2229-2234
19. Russo G.T., Di Benedetto A., Giorda C., Alessi E., Crisafulli G., Ientile R., et al. Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest 34 (2004) 197-204
20. Frederiksen J., Juul K., Grande P., Jensen G.B., Schroeder T.V., Tybjaerg-Hansen A., et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 104 (2004) 3046-3051
21. Aso Y., Okumura K., Takebayashi K., Wakabayashi S., and Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 26 (2003) 2622-2627
22. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
23. Nourooz-Zadeh J., Tajaddini-Sarmadi J., McCarthy S., Betteridge D.J., and Wolff S.P. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44 (1995) 1054-1058
24. Jeremy J.Y., Rowe D., Emsley A.M., and Newby A.C. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 43 (1999) 580-594
25. Hofmann M.A., Kohl B., Zumbach M.S., Borcea V., Bierhaus A., Henkels M., et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21 (1998) 841-848
26. Ouvina S.M., La Greca R.D., Zanaro N.L., Palmer L., and Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 102 (2001) 107-114
27. Balk E.M., Lau J., Goudas L.C., Jordan H.S., Kupelnick B., Kim L.U., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 (2003) 670-682
28. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
29. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
30. Loscalzo J. Homocysteine trials-clear outcomes for complex reasons. N Engl J Med 354 (2006) 1629-1632